<DOC>
	<DOCNO>NCT01333631</DOCNO>
	<brief_summary>This non-randomized phase 2 study evaluate toxicity efficacy valproic acid ( VA ) concurrent chemoradiotherapy ( CCRT ) contain weekly gemcitabine patient unresectable locally advanced pancreatic cancer ( ULAPC ) . All patient plan three-dimensional conformal radiotherapy ( 3-DCRT ) . A total dose 54 Gy deliver use 2 Gy daily fraction give 5 day week.Intravenous ( i.v . ) chemotherapy ( ChT ) gemcitabine 300 mg/m2 start first day 3-DCRT.Total 5-6 weekly dos i.v . ChT planned.VA administer orally daily dose 800 mg . Treatment VA commence first day terminate last day RT.The patient follow till disease progression death .</brief_summary>
	<brief_title>Valproic Acid With Chemoradiotherapy Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Age &gt; 18 year . 2 . Newlydiagnosed , histologically/cytologically CA 19.9 confirm ULAPC 3 . KPS &gt; 60 4 . No previous RT abdomen 5 . No serious comorbid condition Version 1 , December 1 , 2010 6 . No treatment biological response modifier cytotoxic agent within four week prior study entry , apart induction chemotherapy gemcitabine 7 . No participation clinical trial use investigational drug device within four week prior study entry 8 . No serious complication malignant condition 9 . No previous concurrent malignancy sit except cone biopsied situ carcinoma uterine cervix adequately treat basal cell squamous cell carcinoma skin 10 . Adequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &gt; 9.0 Gm/dL WBC count &gt; 4.0x109/L Neutrophile count &gt; 1.5 cell x 109/L , Platelet count &gt; 100 x 109/L , Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; upper limit normal ( ULN ) AST/SGOT &lt; ULN Calcium &lt; ULN 11 . Ability sign inform consent 12 . Ability attend followup visit 1 . Operable disease 2 . Distant metastases 3 . KPS &lt; 60 4 . Previous RT abdomen 5 . Treatment biological response modifier cytotoxic agent induction gemcitabine within four week prior study entry 6 . Participation clinical trial use investigational drug device within four week prior study entry 7 . Major surgical procedure within two week prior study entry 8 . Serious comorbid condition , inclusive limited myocardial infarction within previous six month , uncontrolled cardiac arrhythmia , uncontrolled angina pectoris , active infection include acute hepatitis 9 . Serious complication malignant condition 10 . Previous concurrent malignancy 11 . Inadequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &lt; 9.0 Gm/dL WBC count &lt; 4.0x109/L Neutrophile count &lt; 1.5 cell x 109/L , Platelet count &lt; 100 x 109/L , Creatinine &gt; 1.5 mg/dL Total bilirubin &gt; ULN ( upper limit normal ) AST/SGOT &gt; ULN Calcium &gt; ULN 12 . Inability sign inform consent 13 . Psychological , familial , sociological geographical condition permit regular medical followup compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Locally advanced unresectable pancreatic cancer</keyword>
</DOC>